OBJECTIVE: Adult nesidioblastosis is characterized by endogenous hyperinsulinemia typically causing post-prandial hypoglycemia, and most commonly occurs post-Roux-en-Y gastric bypass. METHODS: We report a unique case of nesidioblastosis occurring in a 67-year-old female. RESULTS: A 5-year history of symptomatic hypoglycemia occurred in a patient with short bowel syndrome and type 2 diabetes mellitus (T2DM) managed previously with a glucagon-like peptide 1 (GLP-1) agonist, which achieved significant weight loss. Continuous glucose monitoring captured 42 hypoglycemia episodes in a 2-week period, and following an oral glucose tolerance test there was the suggestion of a hyperinsulinemia state. She was managed with an open distal pancreatectomy, and subsequently required medical therapy to maintain euglycemia. CONCLUSION: We present the first case of nesidioblastosis occurring in a patient with short bowel syndrome, pre-existing T2DM managed with a GLP-1 agonist which achieved significant weight loss, all of which we speculate could have predisposed to hypoglycemia and development of nesidioblastosis.
OBJECTIVE: Adult nesidioblastosis is characterized by endogenous hyperinsulinemia typically causing post-prandial hypoglycemia, and most commonly occurs post-Roux-en-Y gastric bypass. METHODS: We report a unique case of nesidioblastosis occurring in a 67-year-old female. RESULTS: A 5-year history of symptomatic hypoglycemia occurred in a patient with short bowel syndrome and type 2 diabetes mellitus (T2DM) managed previously with a glucagon-like peptide 1 (GLP-1) agonist, which achieved significant weight loss. Continuous glucose monitoring captured 42 hypoglycemia episodes in a 2-week period, and following an oral glucose tolerance test there was the suggestion of a hyperinsulinemia state. She was managed with an open distal pancreatectomy, and subsequently required medical therapy to maintain euglycemia. CONCLUSION: We present the first case of nesidioblastosis occurring in a patient with short bowel syndrome, pre-existing T2DM managed with a GLP-1 agonist which achieved significant weight loss, all of which we speculate could have predisposed to hypoglycemia and development of nesidioblastosis.
Authors: E P Misiakos; G Agrogiannis; P Patapis; I Dontas; K Petropoulos; N Machairas; E Giamarellos-Bourboulis; T Liakakos; A Machairas Journal: Acta Chir Belg Date: 2013 Mar-Apr Impact factor: 1.090
Authors: Ronald Kefurt; Felix B Langer; Karin Schindler; Soheila Shakeri-Leidenmühler; Bernhard Ludvik; Gerhard Prager Journal: Surg Obes Relat Dis Date: 2014-11-13 Impact factor: 4.734
Authors: A Raffel; M Anlauf; S-B Hosch; M Krausch; T Henopp; J Bauersfeld; R Klofat; D Bach; C-F Eisenberger; G Kloppel; W-T Knoefel Journal: World J Gastroenterol Date: 2006-11-28 Impact factor: 5.742
Authors: Philip E Cryer; Lloyd Axelrod; Ashley B Grossman; Simon R Heller; Victor M Montori; Elizabeth R Seaquist; F John Service Journal: J Clin Endocrinol Metab Date: 2008-12-16 Impact factor: 5.958
Authors: Jess C Hercus; Pouneh Pasha; Sadiq Al Lawati; Peter Kim; Andre Mattman; Douglas Webber; David M Thompson Journal: Case Rep Endocrinol Date: 2022-10-07